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ABSTRACT 
 
PRIMA-1 and its analog APR-246 are novel drugs that restore the active conformation 
of mutated and unfolded p53 protein and induce apoptosis and cell death in various 
tumors in pre-clinical models. We first aimed to explore the effects of APR-246 alone 
and in combination with other drugs in acute myeloid leukemia (AML) in vitro. APR-
246 induced dose-dependent apoptosis and increased active caspase-3 and p53 protein 
levels as well as the Bax/Bcl-2 ratio independently of TP53 mutational status. AML 
patient cells with TP53 mutations and complex karyotype were more resistant to 
conventional chemotherapeutic drugs but retained their sensitivity to APR-246. 
Pronounced synergism was found when combining APR-246 with DNR in AML 
patient cells and pre-incubation with APR-246 induced more synergistic effects 
compared to other treatment schedules in the AML cell line KMB3.  
 
As APR-246 was shown to induce expression of genes protective of oxidative stress in 
global gene expression profiling, we furthermore aimed to study the effects of APR-
246 on the redox status of AML cells. We confirmed that APR-246 increased ROS 
formation and depleted cells from glutathione. HO-1; a gene protecting from oxidative 
stress, was one of the most upregulated genes in response to APR-246. Both HO-1 and 
its transcriptional regulator NFE2L2 (Nrf2) were upregulated as detected by q-RT-
PCR. APR-246 treatment induced Nrf2 activation by translocation of the Nrf2 protein 
from the cytosol to the nucleus. Transient knockdown of Nrf2 in KMB3 cells 
obliterated APR-246-induced up-regulation of HO-1 and increased its antitumoral 
effects. The PI3K inhibitor wortmannin and the mTOR inhibitor rapamycin; both up-
stream regulators of Nrf2, inhibited APR-246-induced nuclear translocation of Nrf2 
and induced synergism with APR-246.  
 
A phase I first-in-man study including 22 patients with hematologic malignancies and 
prostate cancer was conducted. Dose escalations from 2 mg/kg to 90 mg/kg revealed a 
maximum tolerated dose (MTD) of 60 mg/kg and a half-life of 4-5 hours. The most 
common adverse effects were fatigue, dizziness, headache, and confusion. Dose 
limiting toxicities (DLTs) were increased ALT/AST (n=1), dizziness, confusion, and 
sensory disturbances (n=2). Tumor cells showed cell cycle arrest, increased apoptosis, 
and up-regulation of p53 target genes.  
 
We finally showed that miR-34b/c is epigenetically silenced by DNA methylation in 
chronic lymphocytic leukemia (CLL). As being down-stream regulators of p53, miR-
34b/c expression levels were induced by PRIMA-1 as well as by doxorubicin and 
decitabine. Over-expression of miR-34b/c in CLL cells increased apoptosis, which 
suggest a tumor suppressor function for these microRNAs.   
 
In conclusion, AML cells are sensitive to APR-246 in vitro irrespectively of TP53 
mutational status. The substance induces oxidative stress and activates the Nrf2/HO-1 
protective pathway. In a first-in-man study, APR-246 was shown to be to have a 
favorable pharmacokinetic profile and to induce p53-dependent biologic effects in vivo. 
Either in combination with conventional chemotherapeutic drugs or PI3K inhibitors, 
synergistic antileukemic effects can be obtained which holds a promise for further 
combination studies in vivo. 
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1 INTRODUCTION 
1.1 HEMATOLOGICAL MALIGNANCIES  
Hematological malignancies are divided into myeloid or lymphoid depending on the 
origin of the cell type primarily affected. These groups are traditionally subdivided into 
chronic and acute depending on the stage of maturity of the malignant cells and their 
clinical course. 
1.1.1 Myeloid malignancies  
Myeloid malignancies is a group of disorders that manifest them selves as malignant 
dysregulation of the myeloid lineage such as myelodysplastic syndromes (MDS), 
myeloproliferative neoplasms (MPN) including chronic myeloid leukemia (CML), 
myelodysplastic/myelomonocytic neoplasms and acute myeloid leukemia (AML) 1. 
These are clonal diseases that arise in hematopoietic stem or progenitor cells, mainly 
due to mutations in genes involved in signaling pathways (e.g. CBL, FLT3, JAK2, 
RAS), epigenetic regulators (e.g. DNMT3A, ASXL1, EZH2, IDH1, IDH2, SUZ12, TET2, 
UTX), transcription factors (e.g. CEBPA, ETV6, RUNX1), 2 and tumor suppressors (e.g. 
TP53). 
1.1.1.1 Acute myeloid leukemia (AML) 
1.1.1.1.1 Overview and definition of AML 
AML describes a group of different malignant disorders, that originate in the 
hematopoietic system and that present with expansion of undifferentiated myeloid cells 
disturbing normal hematopoiesis. In AML, myeloid progenitor cells in the bone 
marrow undergo a malignant transformation resulting in accelerated production of 
poorly differentiated myeloblasts that are not able to mature into more differentiated 
cell types but remain as immature cells. AML patients present with symptoms resulting 
from bone marrow failure (i.e. anaemia, neutropenia, and thrombocytopenia), and/or 
symptoms resulting from organ infiltration and/or proliferation of leukemic cells (i.e. 
splenomegaly, hepatomegaly, swollen bleeding gums, bone and joint pain, respiratory 
distress and alterations in mental state as well as disseminated intravascular coagulation 
(DIC). 
1.1.1.1.2 FAB classification 
During the last decades and until recently, AML has been classified according to the 
French-American-British (FAB) classification that divides AML into 8 subtypes (M0 to 
M7) defined by morphologic and cytochemic characteristics. The different subclasses 
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represent different states of maturation of the leukemic blast cells and what lineage that 
is engaged. Table 1 shows the different subclasses according to the FAB classification.  
In the FAB classification, the required number of blast cells in the bone marrow is 30% 
compared to less than 5% which is considered to be normal and found in healthy 
individuals.  
Table 1. French-American-British (FAB) Classification of Acute Myelogenous 
Leukemia  
FAB subtype Name 
M0 Undifferentiated acute myeloblastic leukemia 
M1 Acute myeloblastic leukemia with minimal 
maturation 
M2 Acute myeloblastic leukemia with maturation 
M3 Acute promyelocytic leukemia (APL) 
M4 Acute myelomonocytic leukemia (AMML) 
M4 eos Acute myelomonocytic leukemia with dysplastic 
eosinophilia 
M5 Acute monocytic leukemia (AMoL) 
M6 Acute erythroid leukemia 
M7 Acute megakaryoblastic leukemia (AMkL) 
 
Adapted from: Classification of Acute Leukemia, Gamal Abdul-Hamid, 2011 3. 
1.1.1.1.3 WHO classification 
In recent years, the new World Health Organization (WHO) classification has to a large 
extent replaced the FAB classification. The WHO classification is based on the fact that 
an increasing number of acute leukemias should be categorized based upon their 
underlying genetic abnormalities and/or their pathophysiologic characteristics (Table 
2). For AML, the WHO classification requires information on the chromosomal 
aberrations, mutational status, previous exposure to chemotherapy or radiation or to the 
presence of an antecedent myelodysplastic syndrome. Regarding the AML diagnosis, 
there are 2 major differences between the FAB and the WHO classification where in 
the latter, AML is defined by a blast percentage above 20% in the bone marrow 4 or by 
the following chromosomal aberrations: (8;21)(q22;q22), t(16;16)(p13;q22), 
inv(16)(p13;q22), or t(15;17)(q22;q12) 5 regardless of blast percentage.  
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Table 2. Acute myeloid leukemia and related precursor neoplasms, 
and acute leukemias of ambiguous lineage (WHO 2008) Categories 
 
Acute	  myeloid	  leukemia	  with	  recurrent	  genetic	  abnormalities	  AML	  with	  t(8;21)(q22;q22);	  RUNX1-­‐RUNX1T1	  AML	  with	  inv(16)(p13.1q22)	  or	  t(16;16)(p13.1;q22);	  CBFB-­‐MYH11	  APL	  with	  t(15;17)(q22;q12);	  PML-­‐RARA	  AML	  with	  t(9;11)(p22;q23);	  MLLT3-­‐MLL	  AML	  with	  t(6;9)(p23;q34);	  DEK-­‐NUP214	  AML	  with	  inv(3)(q21q26.2)	  or	  t(3;3)(q21;q26.2);	  RPN1-­‐EVI1	  AML	  (megakaryoblastic)	  with	  t(1;22)(p13;q13);	  RBM15-­‐MKL1	  
Provisional	  entity:	  AML	  with	  mutated	  NPM1	  
Provisional	  entity:	  AML	  with	  mutated	  CEBPA	  	  
Acute	  myeloid	  leukemia	  with	  myelodysplasia-­‐related	  changes	  
Therapy-­‐related	  myeloid	  neoplasms	  
Acute	  myeloid	  leukemia,	  not	  otherwise	  specified	  (NOS)	  Acute	  myeloid	  leukemia	  with	  minimal	  differentiation	  Acute	  myeloid	  leukemia	  without	  maturation	  Acute	  myeloid	  leukemia	  with	  maturation	  Acute	  myelomonocytic	  leukemia	  Acute	  monoblastic/monocytic	  leukemia	  Acute	  erythroid	  leukemia	  Pure	  erythroid	  leukemia	  Erythroleukemia,	  erythroid/myeloid	  Acute	  megakaryoblastic	  leukemia	  Acute	  basophilic	  leukemia	  Acute	  panmyelosis	  with	  myelofibrosis	  (acute	  myelofibrosis)	  
Myeloid	  sarcoma	  (extramedullary	  myeloid	  tumor;	  granulocytic	  sarcoma)	  
Myeloid	  proliferations	  related	  to	  Down	  syndrome	  Transient	  abnormal	  myelopoiesis	  (transient	  myeloproliferative	  disorder)	  	  	  	  	  	  	  	  	  	  	  	  	  	  Myeloid	  leukemia	  associated	  with	  Down	  syndrome	  
Blastic	  plasmacytoid	  dendritic	  cell	  neoplasm	  
Acute	  leukemias	  of	  ambiguous	  lineage	  Acute	  undifferentiated	  leukemia	  Mixed	  phenotype	  acute	  leukemia	  with	  t(9;22)(q34;q11.2);	  BCR-­‐ABL1	  Mixed	  phenotype	  acute	  leukemia	  with	  t(v;11q23);	  mixed	  lineage	  leukemia	  	  Mixed	  phenotype	  acute	  leukemia,	  B/myeloid,	  NOS	  Mixed	  phenotype	  acute	  leukemia,	  T/myeloid,	  NOS	  
	  	  	  	  	  	  	  	  	  	  	  	  Provisional	  entity:	  Natural	  killer	  (NK)–cell	  lymphoblastic	  
leukemia/lymphoma	  
 
Adapted from: WHO Classification of Tumours of Haematopoietic 6  and Lymphoid Tissues. Swerdlow 
SH, et al., Lyon, France: IARC Press; 2008 7. 
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1.1.1.1.4 Genetics  
By using novel technologies, such as massively parallel DNA sequencing or high-
resolution single-nucleotide polymorphism arrays, the identification of several novel 
recurrent gene mutations in AML has been facilitated. Nucleophosmin (NPM1) gene 
represent the most frequent genetic aberrations in AML 8, being identified in about 30% 
of AML patients, especially who have a normal karyotype, and in as high as 50–60% of 
de novo AML 9,10. These mutations may contribute to leukemogenesis, at least in part, 
through disruption of genes involved in signalling and apoptosis pathways such as the 
p14ARF - MDM2-p53 pathway 11,12. Abnormalities in the fms-like tyrosine kinase 3 
(FLT3) on chromosome 13 represent the second most common genetic aberrations in 
de novo adult AML 13. It comprises 2 main types: mutations of the FLT3 internal 
tandem duplication (ITD) of the juxtamembrane domain 14 or activating loop mutations 
in the second tyrosine kinase domain (TKD), which occur predominantly at position 
D835 15. FLT3-ITD mutations have been reported in almost 20% of all AML cases 16, it 
occurs in all FAB subtypes , with the highest frequency in M5 17. Mutations in the 
transcription factor CCAAT/enhancer binding protein alpha (CEBPA), which plays a 
central role in normal development of granulocytes, are observed in almost 10% of 
AML patients 18. Point mutations in the RUNX1 gene (also known as AML1 or 
CBFA2) are also seen in specific subtypes of AML such as in AML M0, MDS-AML, 
and secondary (therapy-related) MDS/AML. Though RUNX1 is the most frequent 
target for chromosomal translocation in AML, its mutation alone is not sufficient to 
cause full-blown leukemia 19,20. Other genetic alterations have been identified in AML 
such as: partial tandem duplications (PTD) of the mixed lineage leukemia (MLL) gene, 
as well as mutations in the transforming protein N-Ras (NRAS) and Wilms tumor 
(WT1) genes 21,22. More lately,  novel mutations have been found such as point 
mutations of isocitrate dehydrogenase (IDH1/IDH2) genes 23,24, which affect the 
epigenetic state in AML by inducing increase in global DNA hypermethylation 25. The 
later mutation as well as mutations of the DNA methyltransferase 3A (DNMT3A) and 
the ten-eleven-translocation oncogene family member 2 (TET2) 26 genes are usually 
found in cytogenetically normal AML 27. On the contrary, the additional sex combs-
like 1 (ASXL1) mutations have been found to occur more frequently in secondary AML 
compared to de novo AML cases 28, and were recently reported to be more frequent in 
AML with intermediate risk karyotype 29.  
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Classically, AML mutations have been divided into Class I and Class II to mutations 
(Figure 1) depending on the type of cellular processes that are effected. However, many 
of the newly discovered mutations have not yet been fit into this model.   
 
 
Figure 1. Model of leukemogenesis with two complementation groups of mutations, reviewed by 
(Gaidzik et al, 2008) 21. Reprinted with permission from Elsevier. Seminars in Oncology Journal, 
doi:10.1053/j.;.2008.04.005. 
1.1.1.1.5 Prognostic factors and survival 
Factors that have been identified to influence outcome of adult AML patients and affect 
their classification into different prognostic subgroups include cytogenetics 30, WBC 
count, and whether the disease is primary (de novo) or secondary to a prior hematologic 
malignancy 31. Secondary leukemia includes AML patients with previous exposure to 
chemotherapy and/or radiation (therapy-related AML or t-AML) or patients with an 
antecedent myelodysplastic syndrome or myeloproliferative disorder. The survival of 
patients with secondary AML is generally shorter than for those with de novo AML 
within the same cytogenetic risk group. Other prognostic factors include MDR1 
expression 32,33 and FLT3 34 and NPM1 gene mutational status 35. FLT3 mutations 
confer a poor prognosis 36, especially in patients younger than 60 years old 37. It has 
been shown that mutations of the FLT3 gene, especially FLT3–ITD, are significantly 
correlated to NPM1 mutations (approximately 40%) 38 but show favorable impact in 
older patients 39,40. In younger adult patients, mutated NPM1 without FLT3-ITD usually 
achieve CR and have favorable relapse free survival (RFS) and (overall survival (OS) 
41. A novel study by Wakita, et al. has revealed that mutations of the epigenetically 
modifying gene (DNMT3A, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at 
relapse in de novo acute myeloid leukemia 42. In patients negative for FLT3-ITD 
mutations, mutant NPM1 is associated with improved response to treatment 43. 
Prognostic significance of RUNX1 mutations indicates association with lower CR rate 
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and shorter RFS and OS 41. While CEBPA mutations are associated with higher CR rate 
and favorable RFS and OS. 
1.1.1.1.6 Treatment of AML 
Treatment of acute myeloid leukemia is based on induction therapy and consolidation 
therapy as the following: 
1.1.1.1.6.1 Induction therapy 
Intensive induction chemotherapy aims to achieve a complete remission (CR), which is 
defined as less than 5% leukemic blasts in the bone marrow and recovery of neutrophil 
count >1.0x109/L and platelet count >100x109/L. Conventional induction treatment in 
adults consists of a combination regimen of the deoxycytidine analogue cytarabine and 
an anthracycline antibiotic (daunorubicin or idarubicin) or the anthracenedione 
mitoxantrone, an inhibitor of the topoisomerase IIa enzyme 44. Approximately 50% to 
75% of adults with AML achieve complete remission with that regimen. The most 
commonly used standard induction therapy for the last 4 decades consists of DNR 
intravenously for 3 days and cytarabine 100 or 200 mg/m2  by continuous infusion for 7 
days 45,46. With this standard regimen 60% to 80% of young adults and 40% to 60% of 
older adults can achieve a CR. Many studies have compared the standard regimen with 
different doses of DNR and the conclusion is that 45 mg/m2  (the previous standard 
dose)  should no longer be considered as the standard of care as the higher dose between 
60 and 90 mg/m2 for 3 days has proven to be safe and yield either higher CR and 
prolonged overall survival (OS) rates 47. Some elderly patients tolerate and benefit from 
intensive induction approaches, while others are best managed with less aggressive 
strategies. In order to maximize the therapeutic benefit and minimize toxicity for those 
patients, a strategy to stratify them based on host-related and biological features might 
be investigated 48. 
The European Organization for Research and Treatment of Cancer (EORTC) and the 
Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto (GIMEMA) group study 
AML-10 has shown that the use of mitoxantrone or idarubicin instead of daunorubicin 
enhances the long-term efficacy of chemotherapy in adult patients with AML who have 
not undergone an allogeneic stem cell transplantation (allo SCT) 49 but the results are 
still controversial and the 3-7 regimen using Ara-C in combination with either 
daunorubicin or idarubicin is still considered as standard of care. In 2009, a population-
based study from the Swedish Acute Leukemia Registry reported an improvement in 
the survival of elderly patients up to 80 years of age in the geographical areas where 
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standard induction therapy was mostly given. Moreover, early death rate was also 
lower with intensive therapy than with only palliative therapy, which suggests that the 
standard induction therapy is the best for that patient category 50.  
1.1.1.1.6.2 Consolidation therapy  
Consolidation and maintenance therapy, also known as post-remission treatments are 
given after achieving the first remission (CR1) aiming to maintain the CR and to 
eradicate remaining leukemic cells. Consolidation therapy often includes repeated 
courses with intermediate/high-dose Cytarabine (Ara-C) with or without an 
anthracycline. It is difficult to determine whether reinduction therapy should be 
attempted or hematopoietic cell transplantation should be directly performed in 
relapsed patients with histocompatible donors. Consolidation with allo SCT in CR1 or 
after successful treatment after relapse is an often-preferred treatment option for 
younger patients51,52.  Though, contradictory results showed that patients transplanted 
shortly after achieving CR appeared to have a worse prognosis than those transplanted 
further into remission 53. In a meta-analysis study, it has shown that the efficacy of allo 
SCT depends also on cytogenetic risk for patients in CR1 54.  
 
1.1.2 Lymphoid malignancies  
Lymphoma occurs due to malignant transformation of B- or T-cells. The WHO 
classification of 2008  recognizes three major categories of lymphoid malignancies 55,56 
based on morphology and cell lineage. Those are B-cell neoplasms, T-and natural killer 
(NK)-cell neoplasms and Hodgkin’s lymphoma 57,58. Lymphomas, that constitute the 
major part of the lymphoid malignancies, are usually subdivided into Hodgkin 
lymphoma (HL) and non-Hodgkin lymphoma (NHL), where the latter includes both B- 
and T-cell lymphomas. 
1.1.2.1 Chronic lymphocytic leukemia (CLL) 
CLL belongs to the B-cell NHLs. By their expression of B-cell activation antigens, they 
are considered neoplastic counterparts of normal activated B-cells 59-61. The peripheral 
B-cell neoplasm CLL is the most common leukemia in adults, mostly affecting older 
individuals with the male predominance 62. Proper diagnosis of CLL includes 
evaluation of the peripheral blood count as well as smear and immunophenotyping of 
the bone marrow or peripheral blood. CLL patients present with a specific 
immunophenotype that can be distinguished from other B-cell malignancies. According 
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to a report from the International Workshop on CLL 63, in order to distinguish chronic 
lymphocytic leukemia from monoclonal B-cell lymphocytosis, it was suggested to 
consider a B-cell count of  > 5.0×109/L rather than an absolute lymphocyte count of  > 
5.0 -109/L, as a basis for this differentiation. A few years later, a study from the Italian 
GIMEMA groups assigned the B-cell count of 10×109/L as the best lymphocyte 
threshold to predict time to first treatment of CLL 64.   
1.1.2.1.1 Genetic mutations in CLL 
CLL is characterized by multiple and recurrent chromosomal abnormalities, of which 
deletions in chromosome 13q (del13q14) occur in more than 50 % of all CLL cases. 
Other genetic aberrations are also found to a lesser degree, such as 11q deletions 
(18 %), trisomy of chromosome 12q (12 %), and 17p deletions (7%) 65. These 
abnormalities confer different prognostic risks with 17p deletions being associated with 
the shortest survival.  
1.1.2.1.2 MicroRNAs in CLL 
MicroRNAs (miRNAs) represent a class of noncoding RNAs that regulate messenger 
RNA and protein expression of target genes and has a key role in the posttranscriptional 
regulation of gene expression 66. They negatively regulate gene expression by inducing 
degradation or translational inhibition of target mRNAs. Aberrant expression of 
miRNAs has been recently demonstrated to have an essential role in the process of 
leukaemogenesis 67,68. The targeted gene in 13q deletion has been suggested to be 
microRNA-15a and 16-1 69. On the other hand, research found that certain miRNAs 
such as miR-34 family, and in particular miR-34a represent direct conserved p53 target 
genes, which mediate certain p53-dependent effects including apoptosis, cell cycle 
arrest, and senescence 70. The miR-34 family comprises three processed miRNAs that 
are encoded by two different genes. For miR-34a, its own transcript encodes it, whereas 
miR-34b and miR-34c share a common primary transcript. In a previous CLL study by 
Lehmann et al, SNP-chip technique demonstrated a large commonly deleted region at 
11q, similar to what has been reported previously. However, one case with 11q-
deletions showed two deleted regions with a small heterozygote region in between. One 
of the deleted regions contained the ATM gene whereas the other contained 6 other 
genes (POU2AF1, BTG4, FLJ46266, LAYN, SNFLK2 and PPP2R1) as well as 
microRNA-34b/c 71.  
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1.2 p53 
The cellular tumour antigen gene TP53, encoding the p53 protein, remains the most 
prominent and most commonly mutated tumour suppressor gene and due to its 
function, it has been named “the guardian of the genome” 72. When the genomic 
integrity of a cell is challenged, its fate is determined in part by signals conveyed by the 
p53 protein. The gene is located on chromosome 17p13.1 and the basic modular 
structure of the p53 protein comprises a N-terminal transcriptional activation domain, a 
central DNA-binding domain and a C terminus with oligomeric and regulatory 
activities 73. Several studies have shown that post-translational modifications such as 
serine/threonine phosphorylation, acetylation, prolyl isomerization and sumoylation 
increase the DNA-binding and the transcriptional activity of wild type p53 74,75. 
1.2.1 p53 functions 
The tumor suppressor protein p53 is activated by external and internal stress signals 
that promote its nuclear accumulation in an active form. It plays a central role in cell 
death to prevent cancer development. The spectrum of p53-based cell fate decisions 
ranges from a transient cell-cycle arrest (at G1 and/or G2 phase) enabling damage 
repair to an irreversible block of proliferation through the induction of senescence, 
differentiation or apoptosis 76-78. Disruption of apoptosis-induction process can promote 
tumor progression and chemo-resistance. p53 apparently promotes apoptosis through 
transcription dependent and transcription independent mechanisms, which maintain the 
cell death program.  
1.2.1.1 Transcription-dependent p53-mediated apoptosis 
Active p53 transactivates the transcription of downstream pro-apoptotic mediators, 
including BAX, NOXA, Puma 79 p53AIP1 and CD95 (Fas/APO-1). Those genes 
trigger mitochondrial outer membrane permeabilization 80 with release of the 
apoptogenic proteins; cytochrome c and AIF (apoptosis inducing factor). Cytochrome 
c, by its turn, translocates into the cytosol and promotes the interaction between APAF-
1 and procaspase-9	  81-­‐83,	  which is cleaved into active Caspase-9. Caspase-9 in turn, 
cleaves and activates procaspase-3	  84.  
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Figure 2. The p53 pathway. Reprinted with permission from Nature Publishing Group. Christopher J. 
Brown et al. Nature Reviews Cancer 9, 862-873 (December 2009) | doi:10.1038/nrc2763 85. 
 
1.2.1.2 Transcription-independent p53-mediated apoptosis 
The transcription-independent apoptotic activity of p53 has been linked to the intrinsic 
mitochondrial apoptotic pathway that occurs under different cellular stress conditions 
by two independent yet converging mechanisms 86. These mechanisms involve both the 
mitochondrial and cytosolic p53 respectively. The outcome of activation of p53 by 
either mechanism is the activation of the Bax/Puma and the pro-apoptotic members of 
the Bcl-2 family respectively and thus, induction of the permeabilization of the outer 
mitochondrial membrane (OMM) occurs with the subsequent release of cytochrome C 
and caspase activation 87,88. 
 
1.2.2 Types of p53 mutations in cancer 
The mode of p53 inactivation is diverse including deletion of p53, inhibition of p53 by 
MDM2 or viral proteins 89. Inactivation of p53 function is the most important factor in 
the spectrum of TP53 mutation. Mutations in the TP53 gene are the most frequent 
mutations in human cancers that occur in rates varying between 10% (e.g. in 
hematopoietic malignancies) 90 to 100% (e.g. in high-grade serous ovarian carcinoma) 
91, with average rate of 50% in all cancers 92-94. Many studies suggest that the nature of 
a TP53 mutation in a cell has an impact upon cellular properties, clinical responses to 
therapy and tumor prognosis 95. p53 has five structural and oligomerization domains: an 
N-terminal transactivation domain, a proline-rich domain, a central DNA-binding 
domain, a tetramerization domain and a C-terminal regulatory domain 96. Several 
categories of TP53 mutations can be distinguished by taking into account the impact of 
the mutation on either the protein structure/stabilization or interaction with DNA. 
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1.2.2.1 Missense TP53 mutations 
The most frequent cancer-associated mutations in TP53 are missense mutations, which 
occur in approximately 75% of all human cancers that harbour p53 mutations 97. 
Missense mutations occur due to single residue changes that result in the translation of 
a different amino acid in that position over the full-length (393-amino-acid) of p53 
protein, (such as p53-Trp248 and p53-His273) 98. The missense mutations in the TP53 
gene disrupt the ability of p53 to bind to DNA and consequently to transactivate 
downstream genes. Most of these mutations are clustered within the core domain (102–
292 bp), which is important for DNA-specific binding and is essential for p53 function 
99. Among these mutations in the core domain are six “hot spot” residue substitutions 
(including R175, G245, R248, R249, R273 and R282) that have been reported to occur 
in high frequency, representing almost 30% of the TP53 mutations 100,101. 
1.2.2.2 Gain-of-function TP53 mutations 
Referring to mutant p53 gain-of-function (GOF), various lines of evidence indicate that 
the common types of cancer-associated p53 mutations not only abrogate the tumor 
suppressor functions of wild-type (WT) p53, but also endue the mutant protein with 
new oncogenic activities that can favor the maintenance, the spreading and the chemo-
resistance of malignant tumors 102,103. Even though the cell still retains one WT allele, it 
is rendered practically devoid of WT p53 function. This might be explained by the fact 
that common mutant p53 isoforms can exert dominant–negative effects over 
coexpressed WT p53, by forming mixed tetramers, which prevent the p53 protein and 
its paralogs p63 and p73 from DNA-binding and transactivation, and attenuate their 
function.	  Jie Xu et al. also reported that the dominant-negative activity and GOF effects 
of structurally destabilized p53 mutants result from their increased aggregation which 
also induces misfolding and sequestration of the co-expressed WT p53 and its paralogs 
p63 and p73 into co-aggregates, resulting in complete loss of p53 function and deficient 
transcription of target genes involved in cell growth control and apoptosis 104. 
Understanding the structure and functions of oncogenic p53 mutants may lead to more 
potent reactivation modalities or to the ability to eliminate mutant p53 gain of function 
105. 
 
1.2.3 Treatments targeting p53 
Since TP53 mutations occur frequently in human cancer, this has led to the 
development of numerous approaches to restore wild type p53 in order to revert the 
  12 
malignant phenotype or enhance drug sensitivity. 
1.2.3.1 Mdm2 inhibitors 
The p53 inhibitor Mdm2 (Hdm2 in humans) inhibits the transcriptional activity of p53 
in a negative-feedback loop and, more importantly, promotes its proteasomal 
degradation. Under normal conditions, p53 is a short-lived inactive protein and Mdm2 
is responsible for keeping p53 in this state, as its inappropriate activation can cause 
premature senescence and death 106,107. Following cellular stress this inhibition is 
relieved to stabilize p53. The usage of small molecules to block the Mdm2-p53 
interaction and reactivate the p53 function is a promising therapeutic strategy for the 
treatment of cancers retaining wild type p53. The availability of potent and specific 
Mdm2 inhibitors, such as Nutlin-3 and MI-219, has provided the opportunity to in 
detail examine the molecular mechanism of p53 activation 108. They block the 
intracellular Mdm2-p53 interaction that leads to accumulation of p53 and the activation 
of the p53 pathway in tumor and normal cells. In normal cells, the activation of p53 by 
Mdm2 inhibitors triggers transient cell cycle arrest but no apoptosis, while in tumor 
cells these inhibitors induce both cell cycle arrest and apoptosis 109, thus they exhibit a 
favorable safety profile with the advantage of selectively inducing cancer cell death 
while preserving the normal cells from DNA damage 110. 
 
Figure 3. A model for cooperative control of the p53 pathway by MDM2. Reproduced with permission 
from Journal of Cell Science. http://jcs.biologists.org/content/120/3/371.long doi: 10.1242/jcs.03362 111. 
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1.2.3.2 Adenoviral-based TP53 gene therapy 
Adenoviral vectors have been used for TP53 gene delivery to restore the p53 function 
in TP53 mutated or null tumors. TP53 gene therapy has been tested in clinical trials 
 in patients with lung cancer 112, head and neck cancer 113, ovarian carcinoma 114and 
other tumors. Data from those clinical trials showed favourable outcome, stabilized 
tumor growth or tumor shrinkage in a good fraction of the treated patients 115.  
 
1.2.3.3 PRIMA-1 and APR-246 
1.2.3.3.1  PRIMA-1 and mutant p53 reactivation mechanism 
PRIMA-1 is one of the small molecules that target mutant p53. A methylated form of 
the drug called PRIMA-1MET (also known as APR-246) has been shown to reactivate 
missense mutants of p53 to restore wild type p53 function and thus arrest tumor growth 
116. For example, exposure of cells expressing inactive mutant R175H to PRIMA-1 has 
led to p53 reactivation and subsequent inhibition of cell cycle progression 117. APR-246 
has successfully entered a phase I clinical trial in 2010, which has shown to induce p53-
dependent biologic effects in tumor cells in vivo. The conclusion was furthermore that 
the drug is safe at predicted therapeutic plasma levels and has a favorable 
pharmacokinetic profile 118.  
1.2.3.3.2 PRIMA-1 and protein folding mechanism 
Both PRIMA-1 and APR-246 are able to convert to methylene quinuclidinone (MQ), a 
reactive compound with Michael acceptor activity, which has the ability to modify and 
form adducts with free thiol groups (forming disulfide bond) 117,119.  Disulphide bond 
formation induced by the MQ compound binding may lead to aggregation and 
stabilization of p53 in an active conformation 120. In 1997, a study revealed that certain 
TP53 mutations confers a highly unfolded protein under physiological conditions such 
as the classic structural mutant R175H as well as C242S, R248Q, R249S, and R273H, 
which are less stable. The authors suggested that changes in stability are sufficiently 
small to allow possible therapeutic use of small molecules to rescue p53 function by 
stabilizing/refolding it 121.  PRIMA-1 also has shown to induce both oxidative stress 
and ER stress 122, which propose that additional p53-independent cytotoxic functions of 
PRIMA-1 or one of its degradation products act synergistically with p53 reactivation to 
induce apoptosis 117. Recent studies showed that, small molecules drugs such as 
PRIMA-1 and its analog APR-246 could enhance refolding of the p53 protein to the 
native folded protein conformation, by which the drug can restore the p53 
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transactivation function through converting the unfolded mutant p53 to a folded wild 
type p53 123,124.  
1.2.3.3.3 PRIMA-1 activates microRNAs with a tumor suppressor function 
PRIMA-1 has also been shown to induce expression of miR-34a in the H211 and 
H1155 p53-mutated cells, and knocking down miR-34a decreased the rate of apoptosis 
caused by PRIMA-1. The latter suggests that miR-34a is one of the important 
components of PRIMA-1-induced apoptotic network in the cancer cells expressing 
mutant p53 125. 
 
1.3 OXIDATIVE STRESS  
1.3.1 Oxidative stress in cancer 
Oxidative stress is an imbalance between free radical generation and the antioxidant 
defense system. Redox (reduction-oxidation) regulation has been shown to be an 
important component of malignant cell survival. Although reactive oxygen species 
(ROS) have been considered to cause damage cells, accumulating evidence shows that 
oxidative stress also induces proliferation, gene activation, cell-cycle arrest, and 
apoptosis, depending on the magnitude and duration of oxidative stress activation. The 
most common forms of ROS include superoxide, hydrogen peroxide, and the highly 
reactive hydroxyl radical. 
1.3.2 Oxidative stress as a target in cancer treatment 
In 1997, a study suggested that p53 might induce apoptosis by stimulating the 
production of reactive oxygen species (ROS), where a number of p53-induced genes 
(PIGs) were involved in ROS-mediated apoptosis 126. More recent data suggested that 
oxidative stress induces cytochrome c release from mitochondria and activation of 
caspases, p53, and kinases such as apoptosis signal-regulating kinase 1 (ASK1), c-Jun 
N-terminal kinase (JNK), and p38 mitogen-activated protein kinase (P38 MAPK) 127. 
Recently, new strategies for cancer treatment employed pharmacologic shifting of the 
cellular redox balance in favour of increased intracellular ROS and/or depleting 
protective reducing thiols, such as glutathione, aiming to induction of oxidative stress 
and the subsequent apoptosis 128. Many of the cancer-killing agents such as (ionizing 
radiation, most chemotherapeutic drugs and certain targeted anti-cancer therapies) work 
by a way or another through induction of ROS that block key regulators of the cell 
cycle progression 129.  
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1.3.3 Glutathione in stress response 
Glutathione (GSH) plays an essential role in controlling cellular redox balance and its 
level is considered a significant marker of oxidative stress 130,131. It functions as a 
scavenger of harmful intracellular ROS, preventing ROS-mediated apoptotic signaling 
as well as inhibiting the activity of the stress kinases, ASK1 and p38 132. Several studies 
demonstrated decreased levels of GSH after exposure to certain anticancer drugs such 
as arsenic trioxide 133-135. Reviews by K. Wiman suggest that a reducing environment 
leads to correct p53 folding 120. 
1.3.4 Heat shock proteins in stress response 
Most proteins must fold into defined three-dimensional structures to gain functional 
activity 136. But in the cellular environment, newly synthesized proteins are at great risk 
of aberrant folding and aggregation, potentially forming toxic species.	  The Heat shock 
proteins (HSPs) HSP70s and HSP90s form the major molecular chaperone system that 
assists correct protein-folding processes in mammalian cells. HSP70 mediates the 
correct folding of de novo synthesized proteins and the disassembly of some native 
protein oligomers 137,138. Under stress conditions, HSP70 proteins play multiple roles in 
preserving the protein homeostasis (known as proteostasis), as it prevents protein 
aggregation, actively unfold, solubilize, and reactivate already formed stable (native) 
protein aggregates and enhance refolding of stress-denatured proteins 139.    
1.3.5 ER stress and unfolded protein response  
Folding and maturation of proteins is a primary function of the endoplasmic reticulum 
(ER), which is driven by a diverse array of molecular chaperones and protein-
modification enzymes for protein folding and quality control 140. Cancer cells are often 
exposed to oxidative stress and other deregulations that cause ER stress. ER stress is a 
signaling cascade activated by the cells aiming to restore a proper protein folding 
environment in the ER 141. ER stress also appears to be a potentially useful response to 
many chemotherapeutic drugs 142. As a coping mechanism towards ER stress, cells 
activate a homeostatic signalling network known as the unfolded protein response 
(UPR). UPR transmits information about the protein folding status in the ER lumen to 
the cytoplasm and the nucleus to coordinate the increase in ER folding capacity. The 
later occur through transcriptional up-regulation of ER protein folding and ER-
associated degradation (ERAD) machinery, which is an ubiquitin-proteasomal-
dependent proteolytic process 143,144. Initially activation of the UPR promotes pro-
survival signalling during which the ER refolds the accumulated miss-folded proteins 
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145. However, if the damage is too extensive and homeostasis cannot be restored, the 
UPR ultimately initiates apoptosis 146,147. Drugs that manipulate UPR may thus have 
beneficial and therapeutic effects against cancer by reactivating and refolding the 
inactive unfolded proteins including transcription factors and tumor suppressor genes. 
1.3.6 Nrf2/HO-1 axis as a stress-protective response 
Nuclear factor-erythroid 2-related factor 2 (Nrf2) is a basic-leucine zipper transcription 
factor that activates the antioxidant responsive element (ARE) and thereby upregulating 
the expression of a variety of downstream genes such as Heme oxygenase 1 (HO-1) 
and NADPH:quinone oxidoreductase 1 (NQO1) 148,149 (Figure 4). The activation of 
Nrf2/HO-1 pathway is a reliable indicator of oxidative stress. This stress response 
pathway represents an important antioxidant homeostatic system that counteracts the 
effects of oxidative stress by detoxification of free radicals and repairing oxidant 
damage to the cells. Several studies have reported the activation of HO-1 to be a 
general cellular-protective response that can be stimulated by a large array of chemical 
and physical agents such as heat shock, heavy metals, ionizing radiation and ROS 150. 
In the absence of cellular stress, Nrf2 is hold within the cytoplasm by an inhibitory 
partner, Kelch-like ECH-associated protein 1 (Keap1), which targets Nrf2 to 
ubiquitination and proteasomal degradation 151. Keap1 has a cysteine-rich surface, 
which is subject to oxidation in cases of oxidative stress, allowing Nrf2 to be liberated 
from Keap1 to translocate to the nucleus 152. In this manner, Keap1 acts as a redox-
sensor that upregulates ARE antioxidant responses through Nrf2. Available evidence 
suggests that Nrf2 inducers may block Nrf2 ubiquitination by altering Keap1 
conformation via reaction with the thiols of specific Keap1 cysteines 153,154.  
 
Though it is an antioxidant and ROS detoxifier, elevated expression of Nrf2 and its 
downstream genes, such as HO-1 has been suggested to confer resistance in some 
cancer cell models. Example for that is MCF-7 cells line resistance to tamoxifen. 
Consequently, knocking down of Nrf2, using Nrf2–siRNA, reversed the cellular 
resistance towards tamoxifen 155. 
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Figure 4. Mechanism of Keap1/Nrf2 activation of HO-1 and subsequent antioxidant action. Satoh T et al. 
PNAS 2006;103:768-773. Reprinted with permission. Copyright (2006) National Academy of Sciences 
156.  
 
Studies on the mechanisms of Nrf2 activation have referred to certain upstream kinases, 
such as mitogen-activated protein kinases (MAPK), GSK-3β, JNK and phosphatidyl-
ionositol-3 (PI3K) kinase/Akt/mTOR pathway 157-161. Deregulation of PI3K/Akt/mTOR 
pathway in some AMLs has been shown to result from constitutive activation of Flt-3 
162,163 and it also leads to drug resistance 164. On the other side, Nrf2 activation in AML 
cells encourages their evasion of chemotherapy-induced cytotoxicity 165,166. Thus, 
pharmacologic targeting of the PI3K/Akt/mTOR pathway may have dual benefit in 
AML. Firstly by inhibiting its key survival networks important in leukemogenesis and 
drug resistance. Secondly, by indirectly targeting the cell survival antioxidant Nrf2/HO-
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2 AIMS OF THE THESIS 
 
§ To evaluate the effects of APR-246/PRIMA-1MET on primary AML cells alone 
and in combination with conventional chemotherapeutic drugs and to study 
factors that influence the in vitro sensitivity to APR-246/PRIMA-1MET.  
 
§ To un-biasedly explore the effect of APR-246/PRIMA-1MET on AML cells and 
furthermore to study the effects of the drug on the redox status including the 
role of the Nrf2/HO-1 pathway for the antileukemic effect.   
 
§ To determine the maximum tolerated dose of APR-246/PRIMA-1MET as well as 
to study safety, side effects, pharmacokinetics, biological effects and anti-tumor 
effects in a first-in-man study. 
 
§ To evaluate the epigenetic regulation of miR-34b/c in CLL cells and, 
specifically to this thesis, to study the effects of PRIMA-1 on the transcriptional 
status of miR-34b/c as well as the consequences of over-expression of miR-
34b/c as being a potential tumor suppressor and a down-stream target of p53.  
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3 MATERIALS AND METHODS 
 
3.1 REAGENTS AND DRUGS (PAPER I, II, III & IV) 
PRIMA-1 and APR-246 (PRIMA-1MET) were provided by APREA AB. The 
chemotherapeutic drugs daunorubicin (DNR), doxorubicin, cytarabin (Ara-C), and 
fludarabine were diluted in PBS and kept frozen (–20°C) up to one month. NAC, BSO, 
Wortmannin, 5-aza-2-deoxycytidin (Decitabine) were purchased from Sigma and 
Rapamycin from Invitrogen. APR-246 for the clinical trial (paper III) was a sterile 
solution for infusion and was diluted with 0.9% NaCl before administration. The 
pharmaceutical formulation consists of 150 mg/mL APR-246, 9 mg/mL NaCl and HCl 
(a.q., pH 4). The current shelf life is 30 months when stored at 2 - 8˚C.  
 
3.2 CELL LINES (PAPER I & II) 
KBM3 cells were kindly provided by Dr Beran, MD Anderson, Houston, Texas, 
USA168 and were grown in IMDM culture medium (GIBCO) supplemented with 15% 
FBS (GIBCO) and 2% L-glutamine. NB4 and HL-60 cells were grown in RPMI 
medium supplied with 10% FBS. The cell line was kept at 0,2-0,5x106 cells/ml in a 
humidified 5% CO2 incubator at 37 °C. HG3 cells were provided by Prof Rosenquist in 
Uppsala and kept in RPMI Medium 1640 with Glutamax and HEPES buffer 
(Invitrogen) with 10 % FBS.  
 
3.3 PATIENT SAMPLES (PAPER I & II & IV) 
The regional ethical committee approved all experiments involving human material. In 
paper I, leukemic blast cells from newly diagnosed AML patients were vitally frozen 
and stored at -150°C. Thawed aliquots of frozen samples were cultured in RPMI 1640 
glutamax-1 supplemented with 20% FCS, 25mM HEPES for 24 to 48h immediately 
prior to the experiments.	  Patient data such as complete remission (CR) and survival rate 
as well as the cytogenetic classification and mutational status of TP53 gene were 
recorded. Cytogenetic investigations were performed after 48h culture according to 
routine procedures 169. In paper II, vitally frozen samples were thawed and incubated 
with APR-246 for detection of mRNA expresion levels of HO-1 and NFE2L2 (Nrf2). 
Fresh AML samples were used for the drug combination studies with APR-246 in 
combination with inhibitors of specified pathways.  
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In paper IV, peripheral blood from CLL patients was collected. Cytogenetic status was 
analyzed using standard protocols and IgHV mutational status by PCR amplification 
and sequencing as previously described 170. All samples contained >70% tumor cells 
according to immunophenotyping. Normal lymphocytes were collected from healthy 
volunteers and from mixed leukocyte DNA from multiple donors (Roche). CD19+ 
normal leukocytes were purchased from 3H Biomedicals.  
 
3.4 CLINICAL TRIAL PROTOCOL AND PATIENT CHARACTERISTICS 
(PAPER III) 
The inclusion criteria for the clinical trial were the following: ≥ 18 years of age; ECOG 
Performance Status (PS) 0-2; life expectancy > 2 months; any hematological malignant 
disease or hormone refractory, metastatic prostate carcinoma. Exclusion criteria were 
uncontrolled infection, HIV-infection, severe cardiac, respiratory renal or hepatic 
insufficiency or previous or current neurologic disorder. Patients were included 
regardless of TP53 mutational status.  
 
The study was approved by the Medical Product Agency (MPA) in Sweden and by 
ethics committees. APR-246 was given intravenously as a 2-hour infusion at four 
consecutive days. Treatment was followed by a safety follow up period of an additional 
17 days after which final safety and tumor load assessments were performed. Starting 
dose was 2 mg/kg with subsequent dose increments to 3, 10, 30, 60 and 90 mg/kg. 
Three patients were treated at each dose level; if no DLT occurred, the dose was 
increased to the subsequent level. In case of DLT in one of three patients, three 
additional patients were treated at the same dose level.  
 
3.5 DLT AND MTD DEFINITIONS (PAPER III)   
During the infusion, dose limiting toxicity (DLT) was defined as study drug related 
Common Terminology Criteria for Adverse Events (CTCAE) grade 1 for 
ataxia/incoordination, tremor and confusion; CTCAE grade 2 for 
somnolence/depressed level of consciousness and seizure and other CTCAE grade 2, 3 
or 4 with relation to study drug. During the follow-up period, DLT was defined as any 
study drug related life-threatening event or non-hematologic Adverse Events (AE) of 
CTCAE grade 3 or 4, hematological AE of CTCAE grade 3 or 4 (prostate cancer) or 
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grade 4 (hematological malignancy). Maximum tolerated dose (MTD) was defined as 
the dose level below the level where DLT occurred in either two of three or two of six 
treated patients.  
 
3.6 ASSESSMENTS, BLOOD CHEMISTRY AND PHARMACOKINETICS 
(PAPER III)   
Vital signs assessments and neurologic examinations were performed frequently during 
and after the infusion. Blood chemistry, urine sampling and ECG was performed daily 
during days of treatment and then twice weekly until day 21 in the cycle. A bone 
marrow aspirate was performed for TP53 mutational analysis in hematological patients. 
Blood sampling for PK analyses was performed on each day of treatment. PK samples 
were taken before the start of the infusion, at 30, 60, 120 (end of infusion), 135, 150 
minutes and 3, 4, 6, 10 and 24 hours after start of the infusion. 
 
3.7 ASSAY OF CYTOTOXICITY (PAPER I & II) 
Exposed cells in duplicate were compared to unexposed cells in quadruplicate. Drugs 
were added to the cells at 0.5x105 cells/ml and the incubations were continued for 4 
days. All experiments were performed in triplicate. For determination of drug 
cytotoxicity, cells were extracted in 1.25% trichloracetic acid (TCA) and an automated 
bioluminescence assay was used to determine the ATP levels 171-173. ATP Kit SL 144-
041 (Bio Thema, Haninge, Sweden) was used.  
 
3.8 FLOW CYTOMETRIC ANALYSIS  
3.8.1 Flow cytometric detection of Bax, Bcl-2 and p53  (Paper I) 
Antibodies to detect the expression of p53, Bax, Bcl-2 and active caspase-3 were 
purchased from Becton Dickinson. An all leucocyte CD45 antibody was used to locate 
the leukemic cell population174 and as isotype controls mouse IgG1, differently 
conjugated antibodies from BD were used. After incubation cells were stained 
according to manufacturer’s instructions and fixed and permeabilized and then 
analyzed on a FACSCalibur (BD). 
3.8.2 Flow cytometric analysis of ROS content (Paper II) 
Primary AML patient cells and KBM3 cells were incubated in the appropriate medium 
supplemented with FBS. Cells were treated with 2.5, 5, 15 and/or 25µM APR-246 for 
3, 8, 24 and 48 hrs. Medium was discarded under subdued lighting and replaced with 50 
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µM of the cell-permeant probe 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) 
for 20 min at 37°C. Cells were analyzed immediately by flow cytometry (FACScan). 
As a positive control, cells were loaded with H2-DCFDA as above with hydrogen 
peroxide (100 µM) added 15 min before harvesting the cells for flow cytometry 175. 
3.8.3 Pharmacodynamic studies by flow cytometry (Paper III) 
Cells were isolated by Lymphoprep. For myeloid and B-cell-derived tumors, normal T-
cells were excluded from analysis by magnetic MicroBeads carrying anti-human CD3 
antibodies followed by purification on magnetic LS column (Miltenyi Biotec). 
Flowcytometry analyses were performed on the FACSCalibur instrument. Antibodies 
against NOXA, DcR2, Bax, PUMA and cleaved Caspase-3 were purchased from 
Calbiochem, Abcam, Santa Cruz and Cell Signaling Technologies. The Annexin V 
Apoptosis Detection Kit I (BD) was used for Annexin/PI analyses. Samples were fixed 
with etanol, washed and treated either with RNase A/propidium iodide or with primary 
antibodies. FACS data were analyzed by FCS Express 3.0 software. 
 
3.9 QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION (PCR) 
(PAPER I & II) 
Total RNA was isolated using RNeasy plus mini kit (Qiagen) and cDNA synthesis 
was performed by SuperScript™ RT-PCR system (Invitrogen). Q-RT-PCR was 
performed on the StepOne plus Sequence Detector (Applied Biosystems) 176 using 
SYBR green PCR master mix (MM) together with primers for p14ARF, HO-1, 
SLC7A11, RIT1, ABL and GAPDH while the Universal TaqMan MM was used for 
NFE2L2 (Nrf2) and ACTB (β-actin) TaqMan assays. All samples were normalized to 
one or more of the housekeeping genes β-actin, ABL or GAPDH and the relative 
expression of each gene in the drug-treated samples was calculated and normalized to 
the PBS-treated samples 177, 178.  
 
3.10 MUTATION ANALYSIS OF THE TP53 (PAPER I & III) 
Genomic DNA was isolated using QIAamp DNA Blood Mini Kit. Mutation analysis of 
exons 5-8 (including all TP53 mutational hot spots) was performed in all ex vivo treated 
AML samples (Paper I) as well as in vivo treated patients (Paper III). DNA was 
amplified using PCR primers covering exons 5-8 179. Obtained sequences were 
compared to the reference sequence NC_000017 (www.ncbi.nlm.nih.gov) and 
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deviations were recorded as mutations or polymorphisms. Detected mutations were 
confirmed by a second mutational analysis of the original DNA sample. 
 
3.11 GENE EXPRESSION ARRAYS  
3.11.1 Affymetrix Microarray Analysis (Paper II) 
RNA was extracted according to Qiagen protocol and used microarray analysis on 
Affymetrix platform 1.0 according to manufacturer’s instruction at the BEA core 
facility at Karolinska Univeristy Hospital, Huddinge.  
3.11.2 NimbleGen Microarray Analysis (paper III) 
Total RNA was purified according to Qiagen protocol. Purity and concentration were 
measured by Bioanlyzer (Agilent). After extraction, mRNA was subjected to analysis 
of global gene expression using NimbleGen microarrays (Roche Diagnostics). Data 
were analyzed by IPA software (Ingenuity Systems, Inc.). Supervised clustering was 
performed on the geometric sample means of the respective patient arrays using 
complete linkage hierarchical clustering with the Euclidean distance between each 
patient array as distance metric. 
 
3.12 FLUORESCENCE DETECTION OF TOTAL GLUTATHIONE IN LIVE 
AML CELLS BY THIOLTRACKER (PAPER II) 
Primary AML patient cells were exposed to APR-246 as described, washed and treated 
with 300µl of 20µm Thioltracker Violet dye working solution (Molecular Probes®)180. 
Cell were analyzed in a chamber of a microscope 8-chamber Nunc* Lab-Tek II 
Chamber and RPMI-primed CyGEL™ Sustain were directly overlaid on the cells 181. 
Cells were imaged and processed with fluorescence microscope182. 
 
3.13 IMMUNOFLUORESCENCE DETECTION OF NRF2 PROTEIN (PAPER 
II) 
Cells were washed and resuspended in PBS for cytospin on Superfrost Gold slides. 
Cells were fixed and permeabilized with 4% (w/v) paraformaldehyde and incubated 
with primary mouse antihuman Nrf2 antibody (c-20, Santa Cruz) for 2 hours at room 
temperature, washed, and then incubated with FITC-labeled goat anti-mouse IgG 
antibody. Washed cells were then incubated with DAPI stain and coverslips were 
mounted with prolonged Gold anti-fade reagent. Images were captured on a confocal 
microscope equipped with a 3D digital microscopy workstation 183. 
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3.14 CELL TRANSFECTION BY NEON ELECTROPORATION SYSTEM 
(PAPER II & IV) 
In paper II, KBM3 cells were transfected with Nrf2 siRNA or scramble control siRNA 
(Qiagen), while in paper IV, HG3 cells were transfected with either MiRIDIAN® 
miR34b, miR34c or the miRNA mimic control. Transfection was performed using the 
Neon electroporation system according to the manufacturers protocol 184. For KBM3 
the optimized settings were: 1350 volts, 2 pulses with a band width of 20 ms; while for 
HG3 they were 1450 volts, 3 pulses with a band width of 10 ms. The electroporated 
reaction was done in a 10µl Neon tip added to the wells and incubated at 37 C° for 24 
hr before experiments. The BLOCK-iT™ Fluorescent Oligo control (Invitrogen) was 
used as an indicator of transfection efficiency of electroporation in HG3 cells which 
was evaluated by fluorescent microscope.  
 
3.15 METHYLATION, EXPRESSION AND CHIP ANALYSIS (PAPER IV) 
DNA was extracted and bisulfite treated using the EZ DNA Metylation Kit. DNA 
methylation analysis was performed using methylation specific PCR amplification and 
melting curve analysis (MS-MCA) 185. Validation of BTG4/miR-34b/c methylation was 
done by bisulfite pyrosequencing, performed on a PyroMark Q24 platform186. Primers 
were designed using the Oligo1.0 software (Molecular Biology Insights) or with the 
PyroMark Assay Design software (Qiagen). Gene expression was analyzed using qRT-
PCR with RNU6 as control gene for miR-34b/c and β2-microglobulin for BTG4 on an 
ABI StepOnePlus machine. Chromatin Immunoprecipitation (ChIP) was performed 
using Magnetic LowCell ChIP kit from Diagenode (Denville), using antibodies against 
H3K27me3, H2Az and H3 from Abcam 187.  
 
3.16 STATISTICS (PAPER I & II & IV) 
Mean values with SEM were used for descriptive statistics. Spearman’s test was used 
to test correlations between the in vitro response to different chemotherapeutic drugs. 
Students T-test or the Mann-Whitney were used for comparisons between groups 
when appropriate and the additive model was used for evaluations of drug 
combinations 188. The relationship between promoter methylation and cytogenetic 
aberrations or IgVH status was analysed by the Chi-square test. All p-values are two 
sided, p<0.05 was regarded as significant.  
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4 RESULTS AND DISCUSSION 
 
4.1 PAPER I 
 
4.1.1 APR-246 induces apoptotic cell death at low concentrations and 
increases p53 expression and Bax/Bcl-2 ratio in AML patient cells 
(paper I) 
 
Given the high frequency of disruption of the p53 pathways in human cancers and the 
role of the TP53 status on the response to chemotherapy 95,105,189,190, ways to restore and 
activate p53 function is an attractive strategy in order to improve anti-tumoral effects of 
chemotherapy. In paper I, we studied the preclinical effects of APR-246 in samples 
from 32 AML patients. The IC-50 value in patient cells was similar or slightly lower 
compared to its parent substance PRIMA-1 (5.0 µM) 191.  The in vitro concentrations 
used in this study are well within the tolerable range obtainable in vivo in the results 
from phase I clinical trial (Paper III). The effect was independent of TP53 mutational 
status as well as of the presence of complex karyotype. However, AML cells with 
mutant TP53 were significantly more resistant in vitro to both DNR (p=0,008) and 
fludarabine (p=0,011) as compared to AML cells with wild-type TP53, a difference that 
could not be found with APR-246. Similar findings were shown for AML samples with 
the prognostically poor complex karyotype being more resistant to conventional 
chemotherapeutic drugs but not to APR-246.  
 
We then studied factors that were associated to in vitro sensititity to APR-246. Data 
showed that p53 protein levels were increased by APR-246 to a significantly higher 
degree in primary AML cells that were in vitro sensitive to APR-246 compared to the 
APR-246 resistant patient cells (Figure 1A). This finding suggests an association 
between the degree of cell death and the effect on p53 protein expression. In response 
to apoptotic stimuli, Bax translocates from the cytoplasm to the mitochondria which 
results in permeabilization of the mitochondrial outer membrane and subsequent 
cytochrome c release to the cytosol and further caspase activation 192. Bcl-2 over-
expression has previously been shown to be associated with prolonged survival of 
malignant cells and chemoresistance in AML 193. Bax/Bcl-2 ratio has been shown to 
correlate to p53 upregulation 194  and it was also found to be highly predictive of 
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outcome in a study on adult AML patients 195.  Consistently, we found a significant 
correlation between sensitivity to APR-246, as defined by less than 50% cell survival, 
and an increased Bax/Bcl-2 ratio (p=0,030) (Figure 1B). Moreover, primary AML cells 
with high levels of p14ARF mRNA (expression ratio >0,26) were significantly more 
sensitive to APR-246 but not to other studied cytostatic drugs. The latter might be 
explained by the fact that p14ARF binds to and stabilizes p53 196-198 resulting in 




APR-246 induces synergism in combination with DNR in AML patient cells (paper I) 
Synergism studies were performed in leukemic cells from all the 32 patients with 
AML. Synergism was evaluated by the additive model, based on a ratio value between 
the found and the expected combination effect, as calculated from the exposure of the 
individual drugs alone 188,199. Cells were incubated alone or  
 
 
Table 1 shows the average combination index values for the whole AML cohort 
subgrouped by FAB-classification, karyotype, TP53 mutational status, CR rate and 
survival using APR-246 at 2.5 µM. A subgroup analysis showed no significant 
differences between the examined groups. For DNR, synergism was seen for almost all 
subgroups and the total cohort whereas for Ara-C and fludarabine, mostly additive 
effects were seen. The reason for this pronounced effect with DNR compared to Ara-C 
and fludarabine is unclear. Anthracyclines act through modulation of a wide range of 
proteins including p53 protein activation. Oyan et al. reported attenuated Bcl-2/Bax and 
Bcl-2/Puma ratios in pro-apoptotic direction after administration of DNR in AML 
patients 200. The synergy of APR-246 in combination with DNR may be explained by 
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Table 1. APR-246 combinations with conventional chemotherapeutic 
drugs in vitro in different subgroups of patients with AML 
Category Ara-C Combination (CI) DNR Combination (CI)  Fludara Combination (CI) 
Normal 0.91 0.77 (S) 0.84 
Complex 0.86 0.75 (S) 1.02 
WT p53 0.88 0.74 (S) 0.95 
MT p53 0.88 0.77 (S) 0.95 
CR yes 0.85 0.75 (S) 0.85 
CR no 0.91 0.75 (S) 1.03 
High Survival 0,85 0,76 (S) 0,85 
Low Survival 0,92 0,75 (S) 1,04 
M0  0.96 0.81 1.05 
M1  0.80 (S) 0.66 (S) 1.24 
M2  0.86 0.70 (S) 0.87 
M4 0.98 0.90 0.89 
M5a  0.64 (S) 0.66 (S) 0.81 
M5b 0.91 0.84 0.88 
Multi-lineage 0.89 0.35 (S) 0.82 
Overall 0.88 0.75 (S) 0.95 
Values represent the combination index (CI) where 0.80–1.2 indicates additive, <0.80  
synergistic (S) and >1.2 subadditive effects. APR-246 was used at a concentration  
of 2.5 µM. CR, complete remission; DNR, daunorubicin. 
 
4.1.2 Combination studies with APR-246 in KBM3 cells 
In order to further evaluate the importance of the time sequence by which the cells are 
exposed to the drugs, we examined the sensitivity to APR-246 in the KBM3 cell line. 
Using the additive model 201, we could confirm the occurrence of synergism between 
APR-246 and conventional chemotherapeutic drugs. The AML cell line KBM3 was 
exposed to 10 and 15 µM of  APR-246 in combination with the chemotherapeutic drugs 
DNR, Ara-C and fludarabine either simultaneously or with 24 hour pre-incubation with 
either APR-246 or the cytotoxic drugs. Using simultanuous co-incubation, synergism 
was found only with fludarabine at the highest concentration of APR-246 (Table 2). To 
study whether pre-incubation with APR-246, with the aim of activating p53 before 
adding the cytostatic drugs 202, could create more potent synergism, cells were pre-
incubated with APR-246 for 24 hours before the addition of the cytotoxic drug (Table 
2). Pre-incubation with APR-246 induced synergism with all cytotoxic drugs in KBM3 
cells. However, when pre-incubating cells with the cytotoxic drugs, synergism was 
seen only with fludarabine. The effects may differ between different time schedules and 
pre-exposure of APR-246 seems to give more favorable combination effects. In an 
overall judgment of the rate of synergism induced by APR-246 in combiantion with 
conventional chemotherapeutic drugs, in our hands, APR-246 compared favourable to 
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other experimental drugs, such as tyrosine kinase inhibitors 203. This suggests that APR-
246 has a favorable mechanism of action for combinations with other drugs. The fact 
that pre-incubation showed the best combination effects could be explained by the fact 
that pre-incubation in APR-246 restores the p53 function before the exposure of drugs 
that exert its effects, at least in part, through p53-dependent mechanisms. The p53 
transcription factor trans-activates a wide range of pro-apoptotic genes involved in 
cancer cell elimination, which seems to be essential for response to chemotherapy in 
AML 204. The reason why AML patient cells and KMB3 cells differed with respect to 
which chemotherapeutic drug that induced best synergism is unclear. It may reflect a 
difference between primary cells and cell lines as well as between AML cells with 
different genetic background. This needs to be further addressed in several cell lines 
with different genetic abnormalities.  
 
Table 2. Impact of drug exposure timing effects with APR-246 in combination 













10µM 0,95 0,96 0,90 
15µM 0,92 0,76 (S) 0,88 
Ara-C 
10µM 0,82 0,85 1,07 
15µM 0,88 0,65 (S) 1,08 
Fluda 
10µM 0,81 0,79 (S) 0,68 (S) 
15µM 0,61 (S) 0,60 (S) 0,48 (S) 
Values represent combination index (CI) after either simultaneous incubation or 24 h pretreatment 
 with either APR-246 or a chemotherapeutic drug in KMB3 cells. Cell viability is measured after 4-d 
incubation from start of incubation with the first drug. CI below 0.80 represents synergistic effect (S). 
 
 
4.2 PAPER II 
4.2.1 APR-246 preferentially upregulates genes related to oxidative 
stress and unfolded protein response 
 
In order to investigate the cellular effects of APR-246 on AML cells, we performed 
global gene expression using Affymetrix arrays on KMB3 AML cells after APR-246 
exposure. The most upregulated genes were found to be genes preferentially related to 
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defence mechanisms occurring in response to oxidative stress and heat shock. Three of 
the genes related to protection against ROS; HO-1, SLC7A11, and RIT1 were also 
confirmed by real-time RT-PCR showing a concentration-dependent up-regulation 
between 4 to 14 fold. GO analysis revealed that the most upregulated genes were 
associated with apoptosis, response to protein stimulus, response to unfolded protein 
and cell death. In addition to a protective response against oxidative stress, the global 
gene expression profiling showed that APR-246 also induces elements of UPR such as 
molecular chaperones and heat shock proteins (HSPs) involved in protein folding, 
including HSP70 (HSPA1A and HSPA1B) and HSP40 (DNAJB1 and DNAJB9), 
suggesting that APR-246 induces endoplasmic reticulum (ER) stress and UPR 205 
leukemia cells.  Similarly, it has been reported previously that certain ROS-generating 
drugs such as Fenritinide, induce a pattern of ROS-mediated apoptosis induction, which 
is accompanied by the activation of endoplasmic reticulum (ER) stress and Nrf2. 206. 
 
4.2.2 APR-246 induce intracellular ROS production and reduction in 
glutathione 
 
We could confirm that APR-246 can affect intracellular ROS production in AML cells 
by FACS analysis. Figure 2 shows a dose- and time-dependent increase in ROS 
production in AML KBM3 cells, which was also confirmed in AML patient cells. 
Furthermore, increased HO-1 levels have previously been associated to depletion of 
intracellular glutathione 207. We could also detect a significant dose-dependent 
depletion of glutathione in AML patient cells in response to a 24-hour exposure of 
APR-246 as seen by immunofluorescence. Glutathione (GSH) is a ubiquitously 
expressed tripeptide that serves as the largest source of non-protein thiol groups within 
the cell and plays an important role in controlling the redox balance. Among its 
important intracellular functions is the detoxification of ROS and maintenance of a 
normal redox state 208. BSO, a potent and specific inhibitor of the synthesis of GSH, 
was used in combination with APR-246 in KBM3 cells, which exerted massive 
augmentation of the cytotoxic response towards APR-246 (Figure 3A).  
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Assuming that up-regulation of HO-1 is essential for the effect of APR-246, we 
confirmed that this up-regulation was dependent on ROS production by co-exposing 
cells to APR-246 with a ROS scavenger, NAC. Up-regulation of HO-1 by APR-246 
was significantly inhibited by NAC exposure. Another finding supporting the role of 
ROS production on the effect of APR-246, is the effect of the combination of NAC 
with APR-246 which showed significantly decreased the cell killing by APR-246 in the 
leukemic cells (Figure 3B). Similarly it has been shown that GSH depletion overcomes 
resistance to arsenic trioxide in arsenic-resistant cell lines and that their low GSH 




Prima-meth induction of ROS after 42h in KBM3 cells
of 0, 1µM, 5µM, 10µM and15µM
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4.2.3 APR-246 induced activation of Nrf2 and effects of down-regulation 
of Nrf2 by siRNA  
 
Transactivation of HO-1 is regulated through binding of Nrf2 to antioxidant response 
elements (AREs) in the HO-1 promotor 149,210,211. Upstream of the binding and 
activation of the HO-1 promotor, Nrf2 translocates from the cytosol into the nucleus 
when redox balance is shifted towards the oxidative side.  
 
Figure 4. APR-246 treatment in KBM3 cells induced Nrf2 nuclear translocation.  
 
Therefore, we analyzed the sub-localization of the Nrf2 protein in AML cells exposed 
to APR-246. As shown in Figure 4, APR-246 induced an increase in expression and a 
nuclear translocation of Nrf2 protein in KMB3 cells. We further aimed to investigate 
the role of Nrf2 activation for the induction of HO-1 and for the antileukemic effects of 
APR-246 in AML cells. To study this we transiently knocked down Nrf2 using siRNA, 
which resulted in suppression of APR-246-induced expression of HO-1 cells (Figure 
5A). Furthermore, siRNA transfected cells showed an increased sensitivity to the 
antileukemic effects of APR-246 which suggests a role for Nrf-2 for the antitumoral 
effects of APR-246 (Figure 5B).  
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4.2.4 PI3K/mTOR inhibition counteracts APR-246-induced Nrf2 
translocation and HO-1 activation and induce synergistic cell 
killing with APR-246  
 
Interpreting the Nrf2/HO-1 response to APR-246 exposure as a protective response 
against the antileuekmic effects of APR-246, we aimed to counteract this response 
pharmacologically in order to increase the antileukemic activity by combination 
therapy. As the PI3K/mTOR pathway previously has shown to be an upstream 
mediator of Nrf2 activation 212,213, we used inhibitors of this pathway in combination 
with APR-246. Cells were pre- and co-exposed to the pan PI3K inhibitor wortmannin 
and the mTOR inhibitor rapamycin. Both these inhibitors prevented APR-246 induced 
activation and nuclear translocation of the Nrf2 protein. Furthermore, wortmannin and 
rapamycin inhibited APR-246 induced up-regulation of HO-1 mRNA. Moreover, our 
data showed that wortmannin and rapamycin acted synergistically with APR-246 in 
reducing cell viability, suggesting a role for combination therapies with PI3K/mTOR 
inhibition together with APR-246 (Figure 6A and 6B). We suggest that drugs acting on 
the PI3K and mTOR pathways should be further evaluated in animal models and, if 
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4.3 PAPER III 
 
In this study, we evaluated APR-246 in a first-in-human trial with the main aims to 
establish the maximum tolerated dose (MTD), assess PK and to evaluate safety, but 
also biological and clinical effects. The study included hematological malignances 214-
216 and refractory prostate cancer patients. The trial was initiated at 2 mg/kg and 
patients were subsequently treated at the following dose levels: 3, 10, 30, 60 and 90 
mg/kg.  
4.3.1 Toxicity and pharmacokinetics 
Generally, APR-246 was well tolerated and the toxicity profile was distinctly different 
from that of conventional chemotherapeutic drugs. In total, 38 AEs in 12 patients were 
judged as related to the study drug (Table 3). The most common side effects related to 
the study drug were fatigue followed by dizziness, headache and confusion and other 
neurological side effects such as muscle spasms and sensory disturbances. The side 
effects typically occurred at the end of the infusion or shortly after the infusion and 
continued for hours or in some cases days. All side effects were reversible.  There were 
three patients with dose limiting toxicity (DLT) in the study. One patient at 60 mg/kg 
presented with CTCAE grade 3 increase of liver at Day 3. Therapy was stopped at Day 
4 and the symptoms completely normalized within 10 days. However, no effects have 
been observed on liver enzymes in in vitro preclinical studies and no other evidence of 
hepatic disturbances was seen. The other two DLTs occurred at the 90 mg/kg and were 
judged as mild or moderate. One patient presented with transient mild dizziness 
moderate confusion, mild hallucinations and impaired talking and the third patient with 
DLT presented with transient mild fatigue, dizziness and sensory disturbances. As two 
patients presented with DLT at 90 mg/kg, MTD using a 2 hours IV infusion was 
defined as 60 mg/kg. In preclinical studies, toxicity has been shown to correlate to the 
maximum plasma concentration, which relates to the infusion rate of the drug and not 
to the cumulative dose given. Consequently, and as shown in new animal studies, 
considerably higher doses are expected to be tolerated when the drug is infused at a 
lower infusion rate over a longer period. The effect of higher exposure after prolonged 
infusion is currently evaluated in an extension trial.  
 
 
  34 
Table 3. Number of adverse events by CTCAE grade and system organ class. DLT 
is indicated by an asterisk (*). 
System	  organ	  class	   Symptom	   Grade	  1	   Grade	  2	   Grade	  
3/4	  
Cardiac	  disorders	   Atrial	  fibrillation	   	   1	   	  
Eye	  disorders	   Visual	  impairment	   1	   	   	  
GI	  disorders	   Nausea	  Vomiting	   1	  1	   	   	  
General	  disorders	  	   Fatigue	   3	   2	   	  
Investigations	   Increased	  bilirubin	  	  Increased	  alanine	  aminotransferase	  Increased	  aspartate	  aminotransferase	  
1	   	   	  1*	  	  1*	  
Metabolism	  and	  nutrition	  
disorders	  
Hypocalcaemia	   	   1	   	  
Nervous	  system	  disorders	   Ageusia/	  Dysgeusia	  Headache	  Balance	  disorder	  Sensory	  disturbance	  Dizziness	  Muscle	  contractions	  involuntary	  Dysarthria	  Somnolence	  
2	  	  3*	  2	  	  2*	  2	  	  	  1	  1	  
	  	  	  	  	  2*	  1	  
	  	  	  	  	  1	  	  
Psychiatric	  disorders	   Confusional	  state	  Dysphemia	  Hallucination	  	  
1	  1	  1	  
2*	   	  
Reproductive	  system	  and	  breast	  
disorders	  
Pelvic	  pain	   1	   	   	  
Skin	  and	  subcutaneous	  tissue	  
disorders	  
Alopecia	  Rash	   1	  1	   	   	  
Vascular	  disorders	   Intra-­‐abdominal	  hemorrhage	   	   	   1	  
 
PK data showed neither dose nor time dependency of the drug. A significant correlation 
between clearance and renal function was observed and the metabolic pattern was 
similar in plasma and urine. Systemic exposure to APR-246 increased proportionally 
with the dose and t1/2 in plasma was 4-5 hours. The favorable PK profile with low 
interindividual variation in plasma concentrations enables further clinical development 
of APR-246.   
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4.3.2 Pharmacodymanic and clinical effects 
In 12 out of the 15 patients with hematological malignancies, malignant cells were 
available for mutational analysis of the TP53 gene. TP53 gene mutations were found in 
three (25 %) of analyzed samples (V173M, A355V and a splice site mutation at the 3' 
end of intron 9). Pharmacodynamic and apoptotic studies were performed in the 6 
patients with circulating malignant cells (Table 4). Among them, 4 samples showed cell 
cycle arrest (Figure 7A and 7B) and decrease in cell size, an early sign of apoptosis 217. 
Annexin-V staining was analyzed in 3 patients; all of them showed increased apoptosis. 
Upregulation of pro-apoptotic BAX expression was found in 5 out of 6 tested patients, 
consistent with previous in vitro studies 214,218-220 (paper I).  
 
 Likewise, the p53-responsive genes PUMA and NOXA were upregulated in 3 and 2 
patients, respectively, showing that APR-246 can activate p53 downstream targets in 
tumor cells in vivo.  
Table 4. Flowcytometry analysis of circulating malignant cells at base line 














DcR2 NOXA BAX PUMA 
5-02 10  AML mutated 0 S↓ 
G2/M↑ 
↓ ND + - + +++ 
3-01 10 T-PLL wt 0 0 0 ND - + ++ ++++ 
7-01 30 T-PLL ND 0 0 0 ND - ++ +++ +++ 
5-03 60 CLL mutated 0 S↓ 
G2/M↑ 
↓ + + - ++ - 
3-02 60 AML wt 0 S↓ 
G2/M↑ 
↓ ++ - - - - 
5-04 60 AML wt 0 S↓ 
G2/M↑ 
0 + - - + - 
“0” represents no effect. For protein signal induction: 0-10 % (- [negative]); 10-20 % (+); 20-40 % (++); 
40-60 % (+++); 60-80 % (++++); 80-100 % (+++++). For Annexin V-PI induction: 1.5-2 fold (+); 2-3 
fold (++); 3-4 fold (+++). 
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There is no obvious explanation for the difference in the detected biological effects 
between different diagnoses, but it is not unexpected that different malignant cells 
respond differently and that the difference in the dynamics of cell proliferation and 
apoptosis of various malignant cell types may have an impact on these events. 
 
Global gene expression array analysis was performed on leukemic cells at baseline and 
at the end of the last infusion in 5 of the patients with peripherally circulating malignant 
cells. Figure 8 shows a heatmap of the most differentially expressed genes. APR-246 
induced similar gene expression patterns in leukemic cells from all treated patients. 
Baseline samples from four patients clustered together, and samples from the same 
patients after APR-246 treatment formed a separate cluster. Interestingly, one baseline 
sample clustered together with the treated samples.  
 
Fig 8. Heat map of most differentially expressed genes 
 
This was the baseline sample of cycle number 2 for the only patient who received a 
second course of APR-246 and thus, these cells hade previously been exposed to APR-
246. The mRNA expression levels for pro-apoptotic genes in the array correlated with 
increased doses of APR-246 (Spearman R = 0.72, p < 0.05). Results from the gene 
ontology (GO) analysis on the most differentially expressed genes revealed a repetitive 
pattern involving genes affecting cell growth, cell death and cellular development.  
Ten of 15 hematological patients were evaluable with respect to clinical response and 
in two of these, the treatment showed signs of clinical effects. One AML patient 
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achieved a response with a reduction in blast percentage in the bone marrow from 46 % 
to 26 %. One NHL patient experienced a minor response on a CT scan and three 
patients showed stable disease. Both these patients were among the three patients that 
carried TP53 mutations. Although an interesting finding, these patients are two few to 
draw any firm conclusion regarding the association between TP53 mutational status 
and clinical effect.  
 
In total, the results suggest that APR-246 is safe and has a favourable PK profile and 
when given according to the study protocol, APR-246 induces relevant biological 
effects and examples of clinical effects on tumor burden. A strong rationale and a major 
promise for APR-246 is combination therapy with other drugs. Importantly, APR-246 
has shown synergistic effects in vitro in AML patient cells, especially in combination 
with daunorubicin 221(paper I), suggesting that APR-246 should be evaluated in 
combination with standard induction therapy.  
 
4.4 PAPER IV 
4.4.1 The BTG4/miR-34b/c shared promoter is methylated in CLL but not 
in normal leukocytes and associated with better outcome in CLL 
 
Five of the six genes within the small deleted region at 11q previously described 222 
were selected for methylation analysis (POU2AF1, SNFLK2, PPP2R1, LAYN, 
BTG4/miR-34b/c). Interestingly, we found that BTG4-miR-34b/c shared promoter was 
methylated in 48% (25/52) of the CLL samples, but not in peripheral blood 
mononuclear cells from healthy controls (n=2), in CD19 positive lymphocytes from 
healthy controls (n=2), or in commercially available mixed leukocyte DNA from 
multiple donors. Kaplan-Meier curve analysis of overall survival (OS) in 47 samples 
revealed that samples with methylation had significantly better OS than those without 
in univariate analysis, however, the statistical significance was lost in multivariate 
analysis.   
 
The miR-34b/c analogue miR-34a is located on chromosome 1p and has been 
previously been implicated as a tumor suppressor in CLL 223, making the discovery of 
methylation of the miR-34b/c promoter highly interesting. In addition, the miR-34 
family has been described as a downstream targets of, and responsive to p53 224,225. 
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4.4.2 The miR34b/c promoter is associated with repressive histone 
marks in both normal lymphocytes and CLL 
 
In order to study the relation between expression and methylation, we analyzed miR-
34b/c expression by qRT-PCR in normal peripheral blood and in CLL cells. In 
concordance with previous studies, miR-34b/c were not expressed either in normal 
cells or CLL cells 223.  As expression was suppressed also in unmethylated normal B-
cells, we speculated whether miR34b/c could be epigenetically silenced by H3K27 
trimethylation  (H3K27me3) and then through an epigenetic switch be methylated in 
CLL. We performed ChIP experiments against H3K27 trimethylation (H3K27me3) and 
the histone variant H2Az, which is associated with active transcription. We found high 
levels of H3K27me3 in normal CD19+ lymphocytes consistent with epigenetic 
silencing without DNA methylation, and lower, but still measurable levels, in 5/5 CLL 
samples (p=0.024) regardless of promoter methylation levels. No systematic difference 
of H2AZ levels was detected between normal CD19+ and CLL cells. To validate the 
specificity of the ChIP, the presence of H3K27me3 was analyzed in GADPH and 
SERPINA. As expected, H3K27me3 was found to be less associated with 
transcriptionally active GADPH than with repressed SERPINA. 
 
4.4.3 Transfection of miR-34b and c incresaes apoptosis in HG3 CLL 
cells  
 
In order to study the role of miR-34b/c as a tumor suppressor, we transfected HG3 cells 
with either miR-34b, miR-34c or mock microRNA using the Neon transfection system. 
The transfection efficacy was more than 90 %. Over-expressing both miR-34b and c 
each increased the number of apoptotic cells compared to mock transfected suggesting 
a tumor suppressor role in CLL cells (Figure 9A- 9B).  
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4.4.4 Doxorubicin induces miR-34b/c expression in normal leukocytes 
and selectively in CLL cases according to promoter methylation 
status 
 
To study whether miR-34b/c expression could be induced by stimuli in normal and 
malignant B-cells, we next incubated primary CLL cells and normal CD19+ 
lymphocytes with doxorubicin, an anthracyclin known to upregulate p53 226. 
Experiments are shown in figure 10. We found that miR-34b/c was selectively 
upregulated in samples that were unmethylated (<30% methylation) compared to 
methylated samples (p=0.038). Decitabine incubation could also induce miR-34b/c 
transcripts, but seemingly, the difference between promoter methylated and 
unmethylated samples was attenuated (p=0.61). The p53 activating substance PRIMA-
1 also induced miR-34b/c expression although there was no statistically significant 
difference in the degree of up-regulation between methylated and unmethylated 
samples. The levels of H3K27me3 did not infer different expression levels of miR-
34b/c when samples were incubated with PRIMA-1 or Decitabine (p=0.61). We 
conclude that silenced miR-34b/c expression can be induced by stress signals such as a 
through exposure to a cytotoxic drug, an effect that seem to be dependent on 
methylation status.  
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5 CONCLUSIONS 
 
I. AML cells are sensitive to APR-246 at clinically relevant concentrations and in 
vitro-sensitivity correlates to up-regulation of the p53 protein, increased activity 
of caspase 3, increased bax/bcl-2 ratio and the expression of the p53-regulating 
gene; p14ARF. In addition, APR-246 acts synergistically together with 
conventional AML drugs such as daunorubicin, Ara-C and fludarabine. 
Specifically strong synergism was found with daunorubicin in primary AML 
cells. Data may also suggest that pre-incubation with APR-246 before exposing 
the cells to chemotherapy result in more favorable antileukemic effects.  
 
II. APR-246 induces oxidative stress in AML cells manifested by an increase in 
ROS, depletion of GSH as well as induction of genes that protect cells from 
oxidative stress. The drug activates the Nrf2/HO-1 pathway and by inhibiting this 
pathway, the sensitivity to APR-246 can be significantly increased. Inhibition of 
the PI3K/mTOR pathway can counteract the nuclear translocation of the Nrf2 
protein and its activation of HO-1 leading to synergistic cell killing of AML cells. 
This creates a rational for further evaluation of APR-246 in combination with 
PI3K and mTOR inhibitors. 
 
III. A first-in-man study with APR-246 showed that the drug is safe and has a 
favorable pharmacokinetic profile. The maximum tolerated dose was 60 mg/kg 
using a 2 hours infusion and the dose limiting toxicity was mainly hepatic 
toxicity, dizziness, sensory disturbances and confusion. APR-246 shows 
biological effects including activation of the p53 pathway in tumor cells during 
drug exposure in vivo as well as examples of clinical effects. This study provides 
important data for further development of phase II clinical protocols with 
extended exposures to the drug as well as combination therapies.  
 
IV. The miR-34b/c promoter is epigenetically silenced by DNA methylation in 
chronic lymphocytic leukemia. Our data suggests that miR-34b/c undergo an 
epigenetic switch from silencing by H3K27 trimethylation in normal B-cells to 
methylation in CLL. miR-34b/c expression can be induced by doxorubicin and 
PRIMA-1, both activators of p53. Induction of doxorubicin correlates to the 
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methylation status of the miR-34b/c promoter. Over-expression of miR-34b and c 
in the CLL cell line HG3 induces an increment in the number of apoptotic cells.  
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6 PRELIMINARY RESULTS  
 
Preliminary results:  
 
Our gene expression array in the AML cell line KBM3 revealed that c-myc was among 
the top 10 most down-regulated genes. We have confirmed down-regulation of c-myc 
by APR-246 by real-time PCR in myeloid cell lines and in cells from patients with 
AML. C-myc is a transcription factor with oncogenic properties that has a crucial role 
for transformation in some hematological malignancies such as Burkitt’s lymphoma.  
C-myc has also been suggested as participating in the transformation of AML with 
trisomy 8.  
 
In addition, we have found that APR-246 inhibits phosphorylated ERK 1/2 and MAPK 
on protein level and that the expression of the dual specificity phospahatase 1 (DUSP1),  
the gene regulating dephosphorylation and inactivation of the ERK/MAPK pathway, is 
increased by APR-246. As analyzed by western blot analysis, APR-246 could initially 
activate the stress kinase p38 MAPK in the first 24 hour, with concurrent gradual 
increase of ROS production. At later time points, p38 MAPK showed marked 
inhibition which coincides with parallel time-course increase of the mRNA expression 
level of the stress-buffering gene HO-1, an oxidative-stress-related phenomenon which 
was reported previously by Silva and Cunha et al 227. Moreover, ERK1/2 
phosphorylation was inhibited by APR-246 in a time- and dose-dependent manner. 
Preincubation with NAC, a ROS scavenger blunted the inhibitory effect on ERK 1/2 
and p38 MAPK placing them as downstream targets of ROS. In addition, we have 
shown synergistic effects of APR-246 combination with the MEK1/2 inhibitor 
PD988059 and the MAPK inhibitor SB203580.   
  
These results may provide a mechanism of action for how APR-246 affects changes of 
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Suggested future studies:   
 
1. To further confirm down-regulation of c-myc by APR-246 in cell lines and in cells 
from patients with other types of hematological malignancies.  
 
2. To determine the role of DUSP-1 for inactivation of the ERK/MAPK pathway and 
for c-myc inhibition.  
 
3. To further investigate the effects of APR-246 in combinations with inhibitors of c-
myc pathways, such as: (R)-Roscovitine, 10058-F4 and BML-P605.  
 
4. To determine the role of mutations of the TP53 gene, the effects of APR-246 in cells 
with mutated compared to null and wild type TP53 should be explored. 
 
  44 
7 FUTURE PERSPECTIVES  
 
APR-246 is the first substance targeting cells with mutated p53 that has been taken into 
studies in humans. As TP53 mutations are the most common mutations to occur in 
cancer and as their presence often is related to a high degree of therapy resistance, the 
drug has the potential to become a major advance in the treatment of malignant diseases 
if proven clinically effective.  
 
Most cancer treatments today consist of combination treatments, most commonly with 
chemotherapeutical substances but also to an increasing degree with new targeted drug. 
APR-246 has shown promising synergism in combination with several commonly used 
chemotherapeutical drug in pre-clinical studies and it is now entering in phase II 
clinical trials in combination with such drugs. This is probably the most likely APR-
246 based treatment approach in short term. However, a very interesting and promising 
development is the use of APR-246 together with other new targeting agents. In this 
thesis, we show that combination of APR-246 and inhibitors of PI3K and mTOR 
inhibitors holds a promise, probably based on its interaction with the Nrf2/HO-1 
pathway. However, there many other potential treatment targets that will require further 
insights into the mechanism of action of APR-246.  
 
Another question is the role of TP53 mutations for the effect of the drug. The drug 
apparently effect cells with mutated as well as wild type TP53, probably through 
folding of the unfolded p53 protein. However, these actions of APR-246 needs further 
studies as well as the role of the short lived MQ metabolite versus the mother substance 
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